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A B S T R A C T
Previous studies have reported an involvement of neuroactive steroids as neuroprotective and anti-
inﬂammatory agents in neurological disorders such as multiple sclerosis (MS); an analysis of their proﬁle
during a speciﬁc clinical phase of MS is largely unknown. The pregnenolone (PREG), dehydroepiandros-
terone (DHEA), and allopregnanolone (ALLO) proﬁle was evaluated in cerebrospinal ﬂuid (CSF) in
relapsing-remitting multiple sclerosis (RR-MS) patients as well as those in patients affected by non-
inﬂammatory neurological (control group I) and without neurological disorders (control group II). An
increase of PREG and DHEA values was shown in CSF of male and female RR-MS patients compared to
those observed in both control groups. The ALLO values were signiﬁcantly lower in female RR-MS
patients than those found in male RR-MS patients and in female without neurological disorder. During
the clinical relapse, we observed female RR-MS patients showing signiﬁcantly increased PREG values
compared to female RR-MS patients in stable phase, while their ALLO values showed a signiﬁcant
decrease compared to male RR-MS patients of the same group. Male RR-MS patients with gadolinium-
enhanced lesions showed PREG and DHEA values higher than those found in female RR-MS patients with
gadolinium-enhanced lesions. Similary, male RR-MS patients with gadolinium-enhanced lesions showed
PREG and DHEA values higher than male without gadolinium-enhanced lesions. Female RR-MS patients
with gadolinium-enhanced lesions showed DHEA values higher than those found in female RR-MS
patients with gadolinium-enhanced lesions. Male and female RR-MS patients with gadolinium-enhanced
lesions showed ALLO values higher than those found in respective gender groups without gadolinium-
enhanced lesions.
ALLO values were lower in male than in female RR-MS patients without gadolinium-enhanced lesions.
Considering the pharmacological properties of neuroactive steroids and the observation that
neurological disorders inﬂuence their concentrations, these endogenous compounds may have an
important role as prognostic factors of the disease and used as markers of MS activity such as relapses.
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Multiple sclerosis (MS) is a chronic inﬂammatory demyelinat-
ing disorder of the central nervous system (CNS) [1] characterized
by grey and white matter lesions with inﬁltrating myelin-reactive
lymphocytes and primary or secondary axonal trans-sections
[2–4]. The most common clinical form of MS has a relapsing-
remitting (RR-MS) course, in which the relapses depend on the
formation of new demyelinating lesions or on reactivation of
previously existing ones [5]. While, usually followed by a period of
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lead to sustained disability [6]. Recently, some clinical studies have
focused on the pathophysiologic role of neuroactive steroids in the
course of MS [7]. The nervous system represents a “steroidogenic
organ”. Indeed, both, glial cells and neurons are involved in the
synthesis and metabolism of neuroactive steroids. In this synthesis
cholesterol, mobilized from cytosolic lipid droplets or from
lysosomes, is transported to the inner mitochondrial membrane.
Cholesterol is then converted to pregnenolone (PREG) in a
sequence of three reactions, all catalyzed by the side chain
cleavage enzyme CYP11A. Finally, pregnenolone re-enters the
cytosol and is converted to its metabolite dehydroepiandrosterone
(DHEA) by CYP17 (17a-hydroxylase) [8,9]. Both of these molecules
are known for their neuroprotective effects via modulation of
inﬂammation and promotion of myelination, brain plasticity and
neuronal survival in both, CNS development and the adult
damaged brain [10,11]. Allopregnanolone (ALLO) is another brain
endogenous neuroactive steroid that binds and exerts positive
allosteric modulation on GABAa receptors. ALLO is synthesized in
the brain from progesterone by the sequential action of two
enzymes: (i) 5a-reductase (SRD5A), which reduces progesterone
to 5a-DHP, and (ii) aldo-keto reductase 1C (AKR1C 2/3), which
either converts 5a-DHP into ALLO (reductive reaction) or ALLO
into 5a-DHP [8]. Recently, the alteration of neuroactive steroids
has been closely related to neuroinﬂammation [12], and their
varying levels in plasma and cerebrospinal ﬂuid (CSF) levels
compared to controls were revealed in the experimental autoim-
mune encephalomyelitis (EAE) model of MS [13,14]. In agreement,
neuroprotective effects of these molecules have been reported in
several experimental models of neurodegenerative disorders [15].
For instance, studies in adult animals after brain injury indicate
that neuroactive steroids have an important role in repairing
processes, enhancing myelination and reducing apoptotic pro-
cesses [16]. We perform a cross-sectional study to assess the
neuroactive steroid proﬁle in CSF of RR-MS patients with relapses
(active RR-MS) or remission (stable RR-MS), compared to those
found in patients affected by non-inﬂammatory neurological and
without neurological disorders.
2. Materials and methods
2.1. Study design
The study was carried out on 32 consecutive patients
(20 female, 12 male; median age 38 years, range 28–48) with a
diagnosis of RR-MS according to McDonald criteria [17]. All MS
patients were naive to disease modifying therapy (DMT). Clinical
assessment was performed by Expanded Disability Status Scale
(EDSS) [18]. RR-MS patients underwent diagnostic lumbar
puncture (LP) and magnetic resonance imaging (MRI) at 1.5 T
for brain and spinal cord using gadolinium-based contrast agent
(Gd). The clinical relapse is typically deﬁned as a new or
worsening neurological deﬁcit lasting 24 h or more in the absence
of fever or infections. Among 32 RR-MS patients, 26 were in a
remitting phase and six were in clinical relapse. CSF was collected
before onset of corticosteroids treatment in MS patients with
relapse. Two control groups were included: control group I
consisted of patients affected by non-inﬂammatory neurological
disorders; 30 consecutive age and gender-matched patients
(19 female, 11 male; median age 40 years, range 32–48 years)
affected by idiopathic intracranial hypertension (IIH). The control
group II included patients without neurological disorders:
14 subjects (8 female, 6 male; median age 46 years, range 30–
50 years), who had undergone anesthesia for inguinal hernia
repair. All women reported regular menstrual cycles (range, 21–
35 days), and were medication-free. All women had normalphysical ﬁndings, including gynecologic and breast examination,
normal laboratory test results and a negative pregnancy test
before study entry. They were fertile, did not use hormonal
contraception or hormonal substitution and were in luteal phases
(21st to 28th days). All patients enrolled in the study were not
smokers, and we excluded patients with alcohol-use histories and
were suffering from metabolic and other neurological disorders.
All patients were not in treatment with inﬂuencing steroidogen-
esis, and antipsychotic drugs.
2.2. Ethical statement
This study was approved by the Institutional ethics committee
for biomedical activities “Carlo Romano” Medical School University
Federico II, Naples—(Italy). Informed written consent was obtained
from all patients. The study was performed in compliance with the
good clinical practice guidelines and the principles of the
Declaration of Helsinki.
2.3. Sample collection
CSF samples were obtained by LP between 13:00 p.m. and
15:00 p.m. from 32 MS, 30 non-inﬂammatory neurological and
14 without neurological disorders patients. The samples were
centrifuged immediately after collection and cell-free super-
natants were stored at 80 C for further analysis.
2.4. Gas chromatography–mass spectrometry (GC–MS)
CSF steroid analyses were performed by sensitive and speciﬁc
gas chromatography/mass spectrometry method preceded by
HPLC puriﬁcation, as previously described [19].
CSF samples were homogenized in methanol (75% in H2O)
using a small electric pellet pestle motor (Kontes, Vernon Hills, IL,
USA) on ice and then centrifuged (6000 g for 10 min). Super-
natants were extracted three times with a triple amount of
ethyl acetate, dried under nitrogen before HPLC and containing a
trace quantity (4000 dpm) of tritiated neurosteroid (NEN Life
Science Products, Wellesley, MA) to detect the HPLC fraction of
interest. A constant amount of deuterated pregnenolone (D4-
PREG, 400 pg) was carried throughout the entire procedure as
internal standard. The steroids were isolated using solid-phase
extraction with Oasis HLB cartridges (Waters). The samples were
then derivatized with heptaﬂuorobutyric acid anhydride (Sigma-
Aldrich) and the resultanting derivatives analyzed by gas
chromatography combined with negative ion chemical ionization
mass spectrometry (Agilent 6890 gas chromatographer coupled
to 5973 N mass selective detector). Standard curves were
prepared for each steroid and the samples were injected in
triplicate.
2.5. Statistical analysis
Data were analyzed via Generalized Linear Mixed Model
(GLMM) and p-value 0.05 was considered statistically signiﬁcant.
Baseline variables and MRI data were analyzed by non-parametri-
cally Kruskal–Wallis tests (with Dunn's multiple comparison test)
when appropriate. The Spearman correlation coefﬁcient was used
for the correlation between neuroactive steroids proﬁle and
clinical characteristic. Statistical analysis was performed using
Statistical Analysis System (SAS) software version 9.2. Clinical and
demographic data of all participants presented as mean  standard
deviation (SD). Neuroactive steroids values presented as mean 
standard error of the mean (SEM).
Table 1
Demographic, clinical and neuroimaging characteristics.
Demographic
characteristics
RR-MS CTR
GROUP I
CTR GROUP II
Gender 12/M 11/M 6/M
20/F 19/F 8/F
Age 38  10 y 40  8 y 40  14 y
Clinical and neuroimaging characteristics
RR-MS group N
Patients in clinical remission
Male 11
Female 15
Patients with clinical relapse
Male 3
Female 3
MRI-Gd+
Male 5
Female 9
MRI-Gd-
Male 7
Female 11
EDSS score (mean  SD) 2.5  1.5
F, female; M, male; y, years; RR-MS, relapsing-remitting multiple
sclerosis; CTR GROUP I, non-inﬂammatory neurological disorders;
CTR GROUP II, without neurological disorders; EDSS, expanded
disability status scale; MRI-Gd+, gadolinium enhanced magnetic
resonance imaging lesions; MRI-Gd-, gadolinium-non-enhanced
magnetic resonance imaging lesions. Data expressed as mean 
standard deviation (SD).
N.S. Oreﬁce et al. / Journal of Steroid Biochemistry & Molecular Biology 159 (2016) 1–7 33. Results
3.1. PREG and DHEA values higher in RR-MS patients than in control
groups
Demographic, clinical and neuroimaging characteristics of RR-
MS patients and control groups are reported in Table 1. No
signiﬁcant differences were found in age and male:female ratio
between RR-MS patients and control groups. We found no
signiﬁcant difference of PREG values in male RR-MS patients
compared to those in female RR-MS patients (Fig. 1A); the PREG
values varied signiﬁcantly in male RR-MS patients in respect to
those found in male affected by non-inﬂammatory neurological
and without neurological disorders (Fig. 1A). In accordance to
female gender, we found a signiﬁcant difference in PREG values
between the RR-MS and without neurological disorders groups
(Fig. 1A). We observed no signiﬁcant differences in PREG values
between female RR-MS and female affected by non-inﬂammatory
neurological disorders (Fig. 1A). No signiﬁcant differences were
observed in DHEA values between male and female patients in the
RR-MS group (Fig. 1B). A signiﬁcant increase of DHEA values was
found in male RR-MS patients compared to male patients without
neurological disorders (Fig. 1B). Contrary, no signiﬁcant difference
was found in DHEA values between male RR-MS and male affected
by non-inﬂammatory neurological disorders (Fig. 1B). Similarly,
the female RR-MS patients showed a signiﬁcant increase of DHEA
CSF values compared to female patients without neurological
disorders (Fig. 1B). No signiﬁcant difference was observed in DHEA
values between female RR-MS and female affected by non-
inﬂammatory neurological disorders (Fig. 1B). We failed to ﬁnd
any correlations between the proﬁle of neuroactive steroids and
EDSS, age at clinical onset, and disease duration.
3.2. ALLO values lower in female RR-MS patients
Differently from PREG and DHEA, ALLO values varied signiﬁ-
cantly within the RR-MS group. A signiﬁcant decrease was found of
ALLO values in CSF of female RR-MS compared to male RR-MS
patients (Fig. 1C). In female RR-MS patients the ALLO values in CSFFig.1. Neuroactive steroids proﬁle in relapsing-remitting multiple sclerosis compared to 
patients had signiﬁcantly higher concentrations of PREG in CSF compared to those in bo
PREG values than patients without neurological disorders. (A) **P < 0.01 vs male without 
disorders; *P < 0.05 vs female without neurological disorders (B). Male and female RR-
without neurological disorders. (B) ****P < 0.0001 vs male without neurological disorder
signiﬁcantly higher ALLO values in CSF compared to female RR-MS patients. (C) Values
disorders. (C) *P < 0.05 vs female RR-MS; *P < 0.05 vs female without neurological disowere lower than those observed in the female without neurologi-
cal disease (Fig.1C). No signiﬁcant difference was observed in ALLO
values between female RR-MS and female affected by no-
inﬂammatory neurological disease (Fig. 1C). In accordance to
male gender, we found no differences of ALLO values in CSF
between RR-MS and both control groups (Fig. 1C).non-inﬂammatory neurological and without neurological disorders. (A) Male RR-MS
th control groups. (A) Female RR-MS patients showed signiﬁcantly higher mean of
neurological disorders, *P < 0.05 vs male affected by non-inﬂammatory neurological
MS patients had signiﬁcantly higher values of DHEA in CSF compared to patients
s; **P< 0.01 vs female without neurological disorders. (C) Male RR-MS patients had
 of ALLO in CSF were lower in female RR-MS than in female without neurological
rders. Data was obtained by GC–MS and expressed as pg/ml, mean  SEM.
Fig. 2. Neuroactive steroids proﬁle in MS-related disease activity. (A) Female RR-MS patients in active phase showed signiﬁcantly higher mean values of PREG in CSF than
those observed in female RR-MS patients in stable phase. (A) *P < 0.05 vs female in stable phase. (B) No signiﬁcant differences were observed regarding DHEA values in male
and female RR-MS patients in both groups. (C) Male RR-MS patients in active phase showed signiﬁcantly higher mean values than those observed in female RR-MS active
phase patients. (C) *P < 0.05 vs female active phase. Data obtained by GC–MS is expressed as pg/ml, mean  SEM.
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During the ﬁrst neurological examination, 26 out of 32 patients
were in clinical remission (stable RR-MS) while six patients
experienced clinical relapses (active RR-MS). We observed no
signiﬁcant differences of PREG and DHEA values between male and
female RR-MS patients during active and stable phase (Fig. 2A,B).
Similarly, no signiﬁcant difference was found in CSF of PREG and
DHEA values between male RR-MS (n = 3) active phase and male
RR-MS (n = 11) stable phase patients (Fig. 2A,B). Female RR-MS
active phase patients (n = 3) showed PREG values higher than those
revealed in female RR-MS stable phase patients (n = 15) (Fig. 2A).
DHEA values were not varied between female RR-MS active phase
and female RR-MS stable phase patients (Fig. 2B)
3.4. ALLO values higher in male RR-MS patients in active phase
Differently from PREG and DHEA, ALLO values were higher in
CSF of male (n = 3) than those observed in female (n = 3) RR-MSFig. 3. Neuroactive steroids proﬁle related to the presence (Gd + ) or absence (Gd-) of M
male RR-MS Gd- and female RR-MS Gd+. (A) *** P < 0.001 vs female Gd+, **P < 0.01 vs m
female RR-MS Gd+. (B) DHEA CSF values was higher in female RR-MS Gd+ than female Gd-
ALLO CSF values were higher in male RR-MS Gd+ than in male Gd-. (C) Male RR-MS Gd- 
higher in female RR-MS Gd+ than in female Gd-. (C) **** P < 0.0001 vs male Gd-; *** P < 0.
pg/ml, mean  SEM.active phase patients (Fig. 2C). Despite observing differing ALLO
values comparing male (n = 11) and female (n = 15) RR-MS patients
in stable phase, this data was not signiﬁcant (Fig. 2C). We observed
no difference comparing ALLO values of male and female RR-MS
active phase to those found in CSF of male and female RR-MS stable
phase patients (Fig. 2C).
3.5. PREG and DHEA CSF values at the presence or absence of
gadolinium enhanced lesions
Interestingly, 14 out of 32 RR-MS patients had one or more
gadolinium enhanced lesions (Gd + ). Male RR-MS patients show-
ing Gd+ (n = 5) coincide with a signiﬁcant increase of PREG, and
DHEA values compared to those found in male RR-MS with Gd-
(n = 7) and in female RR-MS patients with Gd+ (n = 9) (Fig. 3A,B). No
signiﬁcant difference was observed in PREG and DHEA values
between male RR-MS with Gd- and female RR-MS patients (n = 11)
with Gd- (Fig. 3A,B). In accordance to female gender, we observed
PREG values were not varied between female RR-MS patients withRI Gd-enhancing lesions. (A) Male RR-MS Gd+ showed higher PREG CSF values than
ale Gd- (B). Male RR-MS Gd+ showed higher DHEA CSF values than male Gd- and
. (B) *** P < 0.001 vs male Gd-; ** P < 0.01 vs female Gd-; * P < 0.05 vs female Gd+. (C)
showed ALLO CSF values lower than in female RR-MS Gd-. (C) ALLO CSF values was
001 vs female Gd-; * P < 0.05 vs female Gd-. Data obtained by GC–MS is expressed as
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were higher in female RR-MS with Gd+ than those found in female
with Gd- (Fig. 3B,C).
3.6. ALLO CSF values higher at the presence of gadolinium enhanced
lesions
Contrary to PREG and DHEA, we observed no signiﬁcant
difference in ALLO CSF values between male (n = 5) and female
(n = 9) RR-MS patients with Gd+ (Fig. 3C). ALLO values were higher
in male RR-MS patients with Gd+ than those found in male RR-MS
patients (n = 7) with Gd- (Fig. 3C). In CSF of male RR-MS patients
with Gd-, the ALLO CSF values were lower than those found in CSF
of female RR-MS patients (n = 11) with Gd- (Fig. 3C). A signiﬁcant
difference was observed in ALLO values between female RR-MS
with Gd+ and Gd- (Fig. 3C).
4. Discussion
Recent evidence underlines the increasing importance of
neuroactive steroids metabolism in the pathogenesis and in the
course of various neurological diseases [20]. Neuroactive steroids
are known to be upregulated in acute neuroinﬂammatory
conditions such as bacterial meningitis or traumatic brain injury
[21,22]. Alterations of neuroactive steroid metabolism is related to
abnormal function of the hypothalamic-pituitary-adrenal (HPA)
axis [23–26]. Dynamics and an increase in activity of the HPA axis
are reported in the majority of MS patients. It exhibits signs ranging
from increased hypothalamic corticotropin-releasing hormone
(CRH) expression, adrenocorticotropic hormone (ACTH) and
cortisol plasma levels [27–29], as well as from enlarged adrenal
gland in MS patients [30]. Also the responsiveness of the HPA axis
to the dexamethasone CRH stimulation test is enhanced in MS
which is related to the clinical type of the disease (i.e., most
prominently in primary-progressive, moderately in relapsing-
remitting and intermediate in secondary-progressive forms of MS)
[31]. This hyperactivity of the HPA axis in MS patients may be part
of our protective mechanism against oncoming disease attacks or
for recovery from relapses [32]. Although dexamethasone resis-
tance suggests that steroid feedback may be implicated in the HPA
axis over reactivity in MS, the exact mechanism of HPA axis
activation is not known. As demonstrated in other diseases [33],
[34,35], the increased HPA axis activity may be related to the
presence of a polymorphism in the gene coding for hydroxysteroid
(11-beta) dehydrogenase 1 (11b-HSD1), an enzyme involved in the
release of cortisol for which we have observed higher values in RR-
MS patients compared to control groups (data not shown) [36].
This polymorphism may have direct functional consequences on
levels of 11ß-HSD1 enzyme activity leading to an accumulation of
cortisol by suppressing its conversion to cortisone. We hypothesize
that this accumulation leads to a reversion of cortisol synthesis
driven by chemical equilibrium and therefore results in higher
values of PREG and DHEA and this may limit inﬂammatory
processes in active phase of MS. We have measured PREG and
DHEA to demonstrate a more global dysregulation of neuroactive
steroids in RR-MS, which is also signiﬁcantly inﬂuenced by disease
activity. In this study, we have also analyzed the neuroactive
steroids proﬁle in the CSF of MS patients during both relapse and
stable clinical phase. To date, none of the available drugs included
in ﬁrst line therapy for RR-MS is totally curative. The primary aims
are: (i) inducing remission after relapse, (ii) reducing the frequency
of new relapses, and (iii) slowing down the progression of the
disability. In this context, it is interesting to note that in our small
cohort of RR-MS patients PREG and DHEA values were higher in
male patients during active and stable clinical phases when
compared to female patients. Considering the possible dual role forPREG and DHEA as neuroprotective and anti-inﬂammatory agents
[37,38], our results are in line with the observation that MS
prevalence in men is lower than in women. The assumption of this
dual role is also supported by our neuroradiological data, which
links Gd+ and Gd- to neuroactive steroids levels. Comparing values
of each of the analyzed neuroactive steroids we observed that Gd+
is associated with signiﬁcantly higher values of PREG in male and
DHEA in male and female patients compared to Gd- (Fig. 3A,B). The
administration of gadolinium contrast agent is indicative of a
disrupted of blood-brain barrier (BBB) in active MS lesions, and
active demyelinated lesions have been associated with inﬂamma-
tion and BBB leakage [39–42]. In this context, it is interesting to
note that PREG, DHEA and ALLO values were higher in RR-MS
patients with GD+ than to those found in patients with GD-. This
would mean that neuroactive steroids are transported from brain
to the circulating blood across the BBB damaged as reported by
Asaba et al. [43]. Similarly to what previously observed by Caruso
et al. [44], a signiﬁcant increase in PREG CSF value was detected in
our male RR-MS patients. However, in the present study, we have
also measured and compared the levels of neuroactive steroids in
CSF of male and female MS patients during clinical remission and
relapse. It is interesting to note that regarding the DHEA CSF, our
values are not in line with those found in male RR-MS patients
reported by Caruso et al. [44]. Our data indicate that DHEA values
are signiﬁcantly increased in male RR-MS patients compared to
those found in absence of neurological diseases. This difference of
ﬁnding should be attributed to analytical methodology applied,
patients’ age at clinical onset (ﬁrst documented sign or symptom),
and/or to the site of lesions in the brain. Remains unresolved an
important question about the dependence of neurosteroidogenesis
on demyelinating lesions in white and grey matter. This could help
to understand the differences existing among our and Caruso’s
observations [44], and verify whether changes in neuroactive
steroids levels may be associated to the site and progression of the
lesions in MS. Among neuroactive steroids, also ALLO portrays an
important endogenous compound since it has been broadly
investigated for its role in promoting regeneration in both central
and peripheral nervous system [45,46]. Thus, ALLO may be a
possible candidate as a neuroprotective neurotransmitter-modu-
lating agent in neurodegenerative diseases. Despite having many
studies supporting this neuroprotective role, most of them are
based on observations in animal models [47]. Indeed, recent
evidence shows that ALLO can induce neuronal generation and
survival in the hippocampus of both aged mice and mice with
experimental Alzheimer’s disease, accompanied by restoration of
associative learning and memory function [48–50]. Only few
studies have investigated ALLO levels in human neuroinﬂamma-
tory diseases such as MS; we assessed the ALLO proﬁle in CSF of RR-
MS patients. Our analysis indicates that, ALLO CSF values were
lower in female RR-MS patients than in male RR-MS (Fig. 1C). This
pattern was not present in male and female control without
neurological diseases (i.e., control group II). The ﬁnding that ALLO
CSF levels in control patients were not different in male vs female
during the luteal phase could be surprising on the basis of
observations present in literature indicating that a signiﬁcative
correlation between CSF and plasma levels of this neuroactive
steroid was reported [51,52] and that in female during luteal phase
ALLO plasma levels are higher in comparison to those observed in
male patients [53]. However, in this context it is important to note
that the signiﬁcant correlation between CSF and plasma has been
demonstrated in postmenopausal women [51,52] and not during
estrous cycle. Signiﬁcant lower ALLO CSF levels in female than in
male patients were also observed during relapses (Fig. 2C).
Similarly to PREG and DHEA values, we observed that ALLO values
are higher in patients with Gd+ compared to Gd- (Fig. 3C). It has
also been suggested that in MS patients a dysregulation of ALLO
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of disease, leading to formation of structurally altered and less
stable myelin [54]. Finally, the comparison with our two different
control groups raises two relevant questions. First, whether the
relapse associated to change of neuroactive steroids in CSF could be
considered important factors predicting of acute status in MS.
Second, the difference in the vulnerability to autoimmune diseases
in both sexes-related dimorphism in autoimmune disease. A large
amounts of information support the fact that hormones are
involved in the immunological dimorphism in males and females
[55,56]. The incidence of MS is higher in female with approxi-
mately a 2:1 ratio [57]; differences in MS symptoms in relation to
the menstrual cycle have been studied in small retrospective
studies showing that female MS experienced more MS symptoms
in the premenstrual phase [58,59] and had exacerbations of MS
starting in the premenstrual period [60]. This could be correlated
with the activity of cytokine-secreting cells indicating that altered
sex hormones levels inﬂuence the cytokine responses to multiple
myelin antigens in autoimmune patients [61–63]. Changes in
disease activity on MRI scans have also been shown to be related to
female steroid sex hormone variation during the menstrual cycle
although the results remain partially contradictory [64–66]. Our
study provides signiﬁcant insights in neuroactive steroid metabo-
lism and their presumptive role in the pathogenesis of MS between
male and female. In particular, we believe that future and large
studies should investigate, with a prospective controlled design,
the impact of neuroactive steroids in MS disease progression.
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